Last reviewed · How we verify
Myasthenia gravis
Approved treatments
- Efgartigimod · M. Peter Marinkovich
Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability. - Ubretid · Torii Pharmaceuticals
- Imuran · Legacy Pharma
- Bloxiverz · Fresenius Kabi
Bloxiverz works by blocking the enzyme acetylcholinesterase, allowing more acetylcholine to be available in the nervous system. - Mytelase · Sanofi
- Vyvgart · Argenx Bv
Vyvgart works by binding to the p51 subunit of the FcRn receptor, preventing it from recycling antibodies back into the bloodstream. - Ultomiris · AstraZeneca
Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells. - ULTOMIRIS · ALEXION PHARM
- Ultomiris · Alexion Pharmaceuticals, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Myasthenia gravis patent landscape — cliff calendar, originator estates, attackable patents
- Myasthenia gravis treatment landscape brief
- Myasthenia gravis treatment updates RSS
Frequently asked questions about Myasthenia gravis
What drugs treat Myasthenia gravis?
Tracked treatments include Efgartigimod, Ubretid, Imuran, Bloxiverz, Mytelase, Vyvgart, Ultomiris, ULTOMIRIS.
What is the treatment for Myasthenia gravis?
Standard treatment for Myasthenia gravis includes Efgartigimod, Ubretid, Imuran, Bloxiverz, Mytelase. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Myasthenia gravis patent cliff · Myasthenia gravis CI report
- Treatment: Efgartigimod · M. Peter Marinkovich
- Treatment: Ubretid · Torii Pharmaceuticals
- Treatment: Imuran · Legacy Pharma
- Treatment: Bloxiverz · Fresenius Kabi
- Treatment: Mytelase · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing